Regorafenib active in metastatic GI stromal tumors

May 23, 2012
Regorafenib active in metastatic GI stromal tumors

(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and sunitinib, according to a study published online May 21 in the Journal of Clinical Oncology.

Suzanne George, M.D., of the Dana-Farber Cancer Institute in Boston, and colleagues conducted a multicenter, single-stage phase II trial of oral regorafenib, 160 mg/day, in 34 patients with advanced GIST after failure of imatinib and sunitinib. The rate (CBR), defined as objective response (partial response and stable disease ≥16 weeks), was the primary study end point.

The researchers found that the CBR was 79 percent for the 33 patients who had received at least two cycles of regorafenib. Of these, 22 patients exhibited stable disease for 16 weeks or longer, and four patients achieved a partial response. Median progression-free survival (PFS) was 10 months. Hypertension and hand-foot-skin reaction were the most commonly observed grade 3 toxicities.

"In summary, regorafenib is a novel orally available multikinase inhibitor with notable activity in patients with advanced GIST after objective failure of both prior imatinib and sunitinib," the authors write. "The median PFS >10 months observed in these heavily pretreated patients supports the hypothesis that regorafenib may be a uniquely active agent in the management of GIST after treatment with imatinib and sunitinib."

Several authors disclosed financial ties to drug companies, including Bayer HealthCare Pharmaceuticals, which provided funding and the study drug.

Explore further: Drug improves survival of colorectal cancer patients, trial results show

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Drug improves survival of colorectal cancer patients, trial results show

January 18, 2012
An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented ...

Longer treatment with cancer drug following removal of GI tumor results in improved survival

March 27, 2012
Among patients with a high risk of recurrence of a gastrointestinal stromal tumor following surgery for its removal, patients who received imatinib (a drug to treat certain cancers) for 3 years instead of 1 had improved recurrence-free ...

ASCO: Dabrafenib/Trametinib active in metastatic melanoma

May 17, 2012
(HealthDay) -- For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic ...

Tivozanib exhibits antitumor activity in renal cancer

April 10, 2012
(HealthDay) -- The potent, selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, tivozanib, demonstrates antitumor activity and is well tolerated in patients with advanced/metastatic renal cell carcinoma ...

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.